This analysis of COVIDENCE UK investigated potential sociodemographic, behavioural, clinical, pharmacological and nutritional determinants of antibody responses to administration of SARS-CoV-2 vaccination and booster doses. It was a pleasure to talk with Professor Adrian Martineau (Queen Mary University of London, London, UK) around the aims, methodology and patient population of the COVIDENCE UK study and to learn which determinants of antibody response were identified.
The abstract ‘Determinants of antibody responses to primary courses and booster doses of SARS-CoV-2 vaccines in 9,101 UK adults‘ (Abstract number: PA1116) was presented at ERS 2022, 4–6 September, 2022.
- Could you give us a brief overview of the COVIDENCE UK study and its achievements to date? (0:11)
- What is known about antibody responses to SARS-CoV-2 vaccination? (1:12)
- What were the aims, methodology and patient population of this study? (2:03)
- What determinants of antibody response were identified? (3:27)
- How can these findings be used to improve antibody responses to vaccination? (5:39)
Disclosures: Adrian Martineau discloses receiving grant/ research support from Barts Charity (ref. MGU0459), Pharma Nord Ltd, the Fischer Family Foundation, DSM Nutritional Products Ltd, the Exilarch’s Foundation, the Karl R Pfleger Foundation, the AIM Foundation, Synergy Biologics Ltd, Cytoplan Ltd, the UK National Institute for Health Research Clinical Research Network, the HDR UK BREATHE Hub, Thornton & Ross Ltd, Warburtons Ltd, Mr Matthew Isaacs (personal donation), and Hyphens Pharma Ltd; serving on advisory boards for Qiagen Ltd; and receiving honoraria from DSM Nutritional Products Ltd, Linus Pauling Institute.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
Share this Video
Related Videos In COVID-19
Hiam Chemaitelly, ICEID 2022: COVID-19 vaccine effectiveness against SARS-CoV-2 variants
The COVID-19 pandemic remains an international public health emergency, and the emergence of new SARS-CoV-2 variants highlights concerns regarding COVID-19 breakthrough infections. Understanding emerging SARS-CoV-2 variants is especially important as the medical and public health community seeks to contain COVID-19. In this interview, Dr Hiam Chemaitelly (Weill Cornell Medicine-Qatar, Ar-Rayyan, Qatar) talked to us about […]
Leila Atmowihardjo, ERS 2022: Imatinib for Acute Respiratory Distress Syndrome Induced by COVID-19
INVENT COVID was a phase II study, which investigated the efficacy and safety of intravenous imatinib in acute respiratory distress syndrome induced by COVID-19 (Clinical Trials Identifier: NCT04794088). touchRESPIRATORY were delighted to speak with Dr. Leila Atmowihardjo (Amsterdam Medical Centers: Academic Medical Center, Amsterdam, The Netherlands) to discuss the aims, design, eligibility criteria and findings […]
Adrian Martineau, ERS 2022: Antibody Responses to SARS-CoV-2 Vaccines – the COVIDENCE UK Study
This analysis of COVIDENCE UK investigated potential sociodemographic, behavioural, clinical, pharmacological and nutritional determinants of antibody responses to administration of SARS-CoV-2 vaccination and booster doses. It was a pleasure to talk with Professor Adrian Martineau (Queen Mary University of London, London, UK) around the aims, methodology and patient population of the COVIDENCE UK study and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!